WHO

4 in 10 elderly excluded on the basis of their age from getting the best health-care, globally. Carta of Florence, the first manifesto against health ageism, released

Retrieved on: 
Tuesday, April 9, 2024
Ageism, Ungar, Longevity, Fundamental, Patient, International Association, Mental health, Hospital, Demography, Social isolation, University, Ageing, Society, Science, Congress, WHO, Health, Nursing

FLORENCE, Italy, April 9, 2024 /PRNewswire/ -- Fondazione Menarini, in the forefront of the fight against discrimination in health-care of the elderly, has contributed to the development of the Carta of Florence.

Key Points: 
  • FLORENCE, Italy, April 9, 2024 /PRNewswire/ -- Fondazione Menarini, in the forefront of the fight against discrimination in health-care of the elderly, has contributed to the development of the Carta of Florence.
  • "Ageism is a global problem: one in two people around the world is moderately or highly ageist toward older people, with a really serious impact.
  • It decreases physical and mental health and increases social isolation," says Alana Officer, head of the department on Demographic Change at WHO and of the Healthy Ageing campaign.
  • "WHO is leading a global campaign to combat ageism and build a broad coalition so that we all work together to eliminate it."

Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin

Retrieved on: 
Monday, March 18, 2024
Survival, JCO, Caregiver, Therapy, Palliative care, Patient, Ethics, Journal, Mouse, Research, Hebrew University of Jerusalem, Anxiety, MD, Nature, Quality of life, Adjustment disorder, World Health Organization, Adjustment, ASCO, Molecular Psychiatry, WHO, Paper, FDA, PBM

NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq:PBM) ("Psyence Biomed" or the "Company") today issued a statement welcoming the results of a recent study finding evidence that nature-derived psilocybin may be demonstrably more therapeutic than synthetic psilocybin.

Key Points: 
  • The study presents evidence that nature (mushroom)-derived psilocybin delivers a “more potent and prolonged effect” on “neuroplasticity” than its synthetic analog.
  • “Neuroplasticity” is increasingly recognized as the gold standard by which the therapeutic efficacy of psychedelic pharmaceutical medicines can be measured.
  • The Psyence Biomed study will examine the use of nature-derived psilocybin as a treatment for Adjustment Disorder due to a recent cancer diagnosis in the Palliative Care context.
  • Neither Psyence Biomedical nor any of its investors or affiliates funded or in any way sponsored the Hebrew University study.

QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements

Retrieved on: 
Monday, March 18, 2024
BCG, IGRA, Disease, Infection, Tuberculosis, World Tuberculosis Day, Incidence, Partnership, Molecular diagnostics, Interferon gamma release assay, CPD, Patient, Ageing, Epidemiology, Genetically modified bacteria, Senior, TST, IPPA, MPH, CDC, Vaccination, QIAGEN, Gold, WHO, TB, Physician, QGEN

Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements.

Key Points: 
  • Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements.
  • A special focus will be on the new Interferon Gamma Release Assay (IGRA) requirements and the associated benefits for patients and healthcare providers.
  • This collaboration follows the U.S. Centers for Disease Control and Prevention (CDC) updating its guidelines for new TB screening requirements for immigrants to the United States.
  • Alexandra Ortega, MPH, MCHES, Executive Director of the IPPA, said, “Working together with QIAGEN allows us to educate panel physicians on the latest TB screening requirements, ensuring patients receive the most accurate and efficient testing available.

Current shareholder and former institutional portfolio manager, Nilesh Undavia, issues an open letter to GrafTech International Ltd. Shareholders

Retrieved on: 
Tuesday, March 12, 2024
Carbon, ACT, TSR, CFO, ALL, Tokai Carbon, IPO, HIS, Adjustment, UNIT, GrafTech, Skin, Proxy, DIRECT, WHO, ABLE, USD, Management

Since 2019 (the first full year after the IPO), GrafTech’s Revenue has declined by 65% and Adjusted EBITDA has collapsed by 98%.

Key Points: 
  • Since 2019 (the first full year after the IPO), GrafTech’s Revenue has declined by 65% and Adjusted EBITDA has collapsed by 98%.
  • Yet, the Board and management appear to have no credible strategy or plan to address the underlying failures of the core business.
  • Currently, the board has only one director out of seven total members1, with outside experience in the steel industry that GrafTech serves.
  • All of the remaining board members appear to lack relevant and transferrable expertise specific to GrafTech.

Merck Continues the Fight against Schistosomiasis in a Storytelling Lab

Retrieved on: 
Tuesday, April 2, 2024
Research, Infectious Diseases, Other Health, Other Education, Health, Pharmaceutical, General Health, Science, Education, Parasitism, Schistosomiasis, Disease, Tablet, SVP, Male, Health education, World Health Organization, Skin, Neglected tropical diseases, WHO, Multimedia, Ministry, Pharmaceutical industry

Merck, a leading science and technology company, announced the winners of its 2024 Bilharzia Storytelling Lab in Ethiopia.

Key Points: 
  • Merck, a leading science and technology company, announced the winners of its 2024 Bilharzia Storytelling Lab in Ethiopia.
  • This innovative initiative aims to develop creative solutions in order to raise awareness about schistosomiasis and, in doing so, bring about behavioral change.
  • View the full release here: https://www.businesswire.com/news/home/20240402803315/en/
    The winners of this year's Merck Bilharzia Storytelling Lab in Ethiopia (Photo: Business Wire)
    Schistosomiasis is one of the most prevalent parasitic diseases and affects more than 240 million people worldwide.
  • Read more about how Merck is committed to eliminating schistosomiasis: www.merckgroup.com/schistosomiasis
    View source version on businesswire.com: https://www.businesswire.com/news/home/20240402803315/en/

Viral Vector and Plasmid DNA Technologies and Global Market Analysis - A USD 7.1 Billion Market by 2028, Expansion of Biotechnological Applications Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 2, 2024
Cardiology, Biotechnology, Health, Pharmaceutical, Oncology, Health Technology, Other Science, Research, Infectious Diseases, Genetics, Science, AAV, Transfection, QC, HSV, Acute lymphoblastic leukemia, Growth, Prevalence, Cell, Incidence, ALL, Tissue, DNA, Mortality, Virus, Cancer, Human, Infection, World Health Organization, Neoplasm, Immunization, Safety, WHO, Therapy, Inosine pranobex, USD, DSM-IV codes, Tisagenlecleucel, Vaccine

The rising incidence and prevalence rate of cancer is considered a key factor in the growth of the global viral vector and plasmid DNA technologies market.

Key Points: 
  • The rising incidence and prevalence rate of cancer is considered a key factor in the growth of the global viral vector and plasmid DNA technologies market.
  • However, regulatory challenges, vector characterization, and QC testing, and manufacturing challenges have restrained growth in the global viral vector and plasmid DNA technologies market.
  • The global viral vector and plasmid DNA technologies market is segmented based on the product, application, and end-user.
  • Based on the product, the global viral vector and plasmid DNA technologies market further is analyzed into plasmid DNA and viral vectors.

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Retrieved on: 
Tuesday, April 2, 2024
Health, Defense, Infectious Diseases, Pharmaceutical, Contracts, Biotechnology, Ulcer, Paromomycin, Patient, NTD, IND, Metronidazole, Francisella tularensis, Infection, OTCQX, Therapy, Priority review, USD, Risk, Systemic, NIH, Anthrax, Arrangement, World Health Organization, Investigational New Drug, Calendar, Scar, Neglected tropical diseases, Tablet, Public, Research, News, PRV, Acquisition, TSX, Drug development, Population health, Cutaneous leishmaniasis, Canada Business Corporations Act, FDA, Transaction, Government, Growth, Entrepreneurship, Skin infection, Share, Procurement, WHO, Pharmaceutical industry

The U.S. FDA's approval of LIKMEZ highlighted Appili’s capacity to identify and develop significant opportunities within the infectious disease domain.

Key Points: 
  • The U.S. FDA's approval of LIKMEZ highlighted Appili’s capacity to identify and develop significant opportunities within the infectious disease domain.
  • Appili licensed the manufacturing and commercialization rights in the U.S. and other selected territories to Saptalis Pharmaceuticals, LLC (“Saptalis”).
  • Appili, in collaboration with Saptalis, continued the product's development, ultimately achieving FDA approval in the United States.
  • With FDA approval, future revenue is expected to be derived from milestone payments and royalties from Saptalis under the license agreement.

Synthetic Hormones Market Research Report 2024: Development of New Delivery Systems and Formulations, & Demand for HRT - Global Analysis and Forecast, 2023-2033 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 27, 2024
Pharmaceutical, Health, Other Health, Hospital, Peptide, Birth, Hypothyroidism, Biotechnology, Prevalence, Growth, Human body, Incidence, Insulin, Diabetes, Patient, Conditional sentence, Research, Menopause, World Health Organization, Investment, Skin, Hormone replacement therapy, Safety, HRT, WHO, Region, Administration, Ageing, Pharmaceutical industry

The development of new delivery systems and formulations that enhance patient compliance and reduce side effects further fuels the market growth.

Key Points: 
  • The development of new delivery systems and formulations that enhance patient compliance and reduce side effects further fuels the market growth.
  • Overall, the synthetic hormones market is expected to continue growing, driven by the need for effective treatments for hormonal disorders and the ongoing research and development in this field.
  • The increasing occurrence of hormonal disorders, including hypothyroidism, diabetes, and imbalances, plays a crucial role in propelling the synthetic hormones market.
  • The hospital pharmacies segment accounted for the largest share of the global synthetic hormones market (by end user) in 2022.

FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)

Retrieved on: 
Tuesday, March 26, 2024
Cardiology, Biotechnology, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Other Health, MSD, FC, Exercise, Breakthrough therapy, Blood, Risk, Patient, Orthostatic hypertension, MRK, World Health Organization, Heart, WHO, Multimedia, PAH, Food, Pharmaceutical industry

“The Pulmonary Hypertension Association welcomes the development of new therapies for those with PAH,” said Matt Granato, president and chief executive officer, Pulmonary Hypertension Association.

Key Points: 
  • “The Pulmonary Hypertension Association welcomes the development of new therapies for those with PAH,” said Matt Granato, president and chief executive officer, Pulmonary Hypertension Association.
  • In the WINREVAIR treatment group, the placebo-adjusted median increase in 6MWD was 41 meters (95% CI: 28, 54; p
  • The median treatment difference in PVR between WINREVAIR and placebo was -235 dynes*sec/cm5 (95% CI: -288, -181; p
  • The median treatment difference in NT-proBNP between WINREVAIR and placebo was -442 pg/mL (95% CI: -574, -310; p

Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes

Retrieved on: 
Tuesday, March 26, 2024
Other Philanthropy, Biotechnology, Pharmaceutical, Managed Care, Oncology, Health, Philanthropy, Clinical Trials, Well, Diagnosis, BMY, World Health Organization, Patients Association, Less, Organization, Social, Education, Bone marrow, Survival, Health equity, Social support, Genetics, Patient, Good Health, Corporate Affairs, Pancreatic cancer, Cancer, Anti-transglutaminase antibodies, Bristol Myers Squibb, Blood Cancer UK, United, Telephone numbers in Hungary, Sistema, Oral cancer, Clinical trial, WHO, Multimedia, Hepatocellular carcinoma, Nursing

Bristol Myers Squibb (NYSE: BMY) today unveiled a $1.8 million initiative to advance health equity by addressing social determinants of health (SDoH) in four countries with underserved patient needs, including Brazil, India, Thailand, and the United Kingdom.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today unveiled a $1.8 million initiative to advance health equity by addressing social determinants of health (SDoH) in four countries with underserved patient needs, including Brazil, India, Thailand, and the United Kingdom.
  • The new health equity grants are an extension of the company’s broader long-term commitment to invest $150M in health equity by 2025 .
  • At Bristol Myers Squibb, health equity is the opportunity for all people and communities across the globe to attain their full potential for health and well-being.
  • Our work extends beyond traditional healthcare boundaries, emphasizing the importance of community voices and cross-sector partnerships in co-creating solutions that drive meaningful and equitable health outcomes worldwide.